Company intelligence / Profile preview

Sellonet

New York City, New York, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

SELLAS has two main product candidates. Galinpepimut-S (GPS), a cancer immunotherapy targeting WT1 protein, has shown promise in hematologic and solid tumors. SLS009 (tambiciclib), a selective CDK9 inhibitor, demonstrated preclinical efficacy against ASXL1-mutated colorectal cancer lines and is advancing through clinical trials. GPS+ is at the preclinical stage.

Therapeutic areas: OncologyNeurology
Modalities: Cancer immunotherapeutic agentSmall molecule
Industry: Biotech

Partnerships

Memorial Sloan Kettering Cancer Center — exclusive global collaboration for GPS development/licensingGenFleet Therapeutics — license agreement for CDK9 inhibitor outside Greater China3D Medicines — license agreement for GPS/GPS+ in Greater China region

Beyond the preview

Go deeper on Sellonet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sellonet.

Explore the full profile